People
Genevieve P. Kanter, PhD
Senior Scholar, USC Schaeffer Institute
Associate Professor of Public Policy, USC Sol Price School of Public Policy

Biography
Genevieve P. Kanter, PhD, is an associate professor of public policy at the USC Sol Price School of Public Policy.
She is an economist whose research focuses on the FDA and regulatory issues related to biomedical technologies; financial conflicts of interest; industry relationships and industry influence in medicine; and hospital and physician payment models.
She serves on the Medicare Evidence Development & Coverage Advisory Committee, the federal committee that advises on Medicare coverage, and has served as Chair of the Advisory Committee for the AcademyHealth Health Economics Interest Group.
Her research and essays have been published in leading academic journals, including the New England Journal of Medicine, JAMA, and Health Affairs, and her work and expert commentary have been featured in major media outlets, including the New York Times, Wall Street Journal, Washington Post, CNBC, Forbes, Wired, AP, NPR, and the Chicago Tribune.
Kanter received a PhD in Economics and in Sociology from the University of Chicago; completed an NIH postdoctoral fellowship in health and demography at Princeton University; and completed research fellowships in health policy and ethics at Massachusetts General Hospital and Harvard University.
Latest Research View All
In The News View All
STAT
Kanter discusses modernizing industry payment transparency to keep pace with medical AI adoption
Featured Experts: Genevieve P. Kanter
KFF Health News
FDA’s shift away from independent drug reviews could shield the agency from scrutiny, Kanter says
Featured Experts: Genevieve P. Kanter
Bloomberg
Kanter interviewed on her research finding key vaccine committees had historically low levels of reported conflicts
Featured Experts: Genevieve P. Kanter
Associated Press
FDA’s use of ad hoc ‘expert panels’ may be used to legitimize predetermined views and create a false appearance of consensus, Kanter says
Featured Experts: Genevieve P. Kanter
Bloomberg Law
Kanter quoted on new FDA drug center chief’s industry ties
Featured Experts: Genevieve P. Kanter
STAT
FDA staff cuts may undermine agency promises on “radical transparency” and fewer conflicts of interest, Kanter explains
Featured Experts: Genevieve P. Kanter